WO2023241675A1 - 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 - Google Patents
一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 Download PDFInfo
- Publication number
- WO2023241675A1 WO2023241675A1 PCT/CN2023/100589 CN2023100589W WO2023241675A1 WO 2023241675 A1 WO2023241675 A1 WO 2023241675A1 CN 2023100589 W CN2023100589 W CN 2023100589W WO 2023241675 A1 WO2023241675 A1 WO 2023241675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- seq
- amino acids
- nucleatum
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 125
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 112
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 112
- 241000605986 Fusobacterium nucleatum Species 0.000 title claims abstract description 57
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims abstract description 9
- 238000013461 design Methods 0.000 title claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 title abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 59
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 13
- 235000001014 amino acid Nutrition 0.000 claims description 44
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 20
- 239000003242 anti bacterial agent Substances 0.000 abstract description 9
- 229940088710 antibiotic agent Drugs 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 241000894006 Bacteria Species 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 230000002147 killing effect Effects 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 8
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 101800004192 Peptide P1 Proteins 0.000 description 1
- 101800004191 Peptide P2 Proteins 0.000 description 1
- 101800004196 Peptide P4 Proteins 0.000 description 1
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241001499297 Vibrio cholerae H1 Species 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 201000009329 acute pericementitis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of polypeptides, in particular to a polypeptide and its design method and its application in the preparation of products that inhibit Fusobacterium nucleatum (F.nucleatum for short) or drugs for preventing colorectal cancer.
- F.nucleatum mainly exists in the human oral cavity. It is a harmful commensal bacterium for humans and is directly involved in oral diseases such as acute and chronic periodontitis, gingivitis, and root canal infection. F.nucleatum has also been found to be associated with a range of diseases, including colorectal cancer, inflammatory bowel disease, appendicitis and other intestinal diseases, as well as respiratory infections, adverse pregnancy outcomes, cardiovascular disease, brain aneurysms, and rheumatoid arthritis. Diseases such as Alzheimer's disease.
- F.nucleatum can be killed by broad-spectrum antibiotics and acute F.nucleatum infection can be cured by antibiotics, antibiotics have the side effect of killing normal flora and therefore cannot be used for long periods of time. Once antibiotics are discontinued, F.nucleatum, as a commensal bacterium in humans, can easily return to a higher load in the human body, thereby increasing the risk of recurrence of acute and chronic infections and promoting the occurrence and development of the above-mentioned F.nucleatum-related diseases. .
- the present invention provides a polypeptide for F. nucleatum whose amino acid sequence is symmetrically distributed and includes hydrophobic amino acids and charged amino acids. Some versions of the polypeptides have antibacterial activity against F. nucleatum, and some versions have antibacterial activity against F. Specific bactericidal effect of nucleatum. Since the polypeptide has a specific bactericidal effect on F.nucleatum without killing the host's normal flora, the polypeptide can be used to reduce the F.nucleatum load in the host, thereby treating or long-term preventing F.nucleatum-related diseases. .
- One object of the present invention is to provide a polypeptide, which includes hydrophobic amino acids and charged amino acids, and the amino acid sequence of the polypeptide is distributed in a symmetrical structure.
- the amino acid sequence of the polypeptide is symmetrically distributed on both sides with proline and glycine as the center.
- Proline and glycine provide ⁇ -turns, so that the polypeptide obtains a ⁇ -sheet structure.
- the total charge range of the polypeptide is from 0 to +8.
- the charged amino acid includes a positively charged amino acid and/or a negatively charged amino acid, the negatively charged amino acid is glutamic acid and/or aspartic acid, and the positively charged amino acid is histidine. , at least one of lysine and arginine.
- two adjacent charged amino acids with the same charge are arranged at intervals and provided with one or more differently charged or uncharged amino acids.
- the hydrophobic amino acid is tryptophan.
- the hydrophobic amino acid proportion range is 40%-50%.
- the total length of the polypeptide ranges from 10 to 20 amino acids.
- amino acid sequence of the polypeptide is such as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO. .7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11 or SEQ ID NO.12.
- the second object of the present invention a polypeptide design method, including the following steps:
- the third object of the present invention is the application of a polypeptide in the preparation of products that inhibit Fusobacterium nucleatum or prevent colorectal cancer.
- the polypeptide includes amino acid sequences such as SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11 and SEQ ID NO.
- One or more polypeptides shown in .12 have antibacterial effects on Fusobacterium nucleatum, and the bactericidal mechanism is achieved by destroying the cell wall of F. nucleatum.
- the polypeptide includes a polypeptide with an amino acid sequence as shown in SEQ ID NO.8 and/or SEQ ID NO.11, which has specific antibacterial activity against F.nucleatum, that is, against F.nucleatum other than F.nucleatum.
- the test bacteria have no or only low antibacterial activity.
- the dosage of the polypeptide is 20 mg/kg, and the drug subject is mice.
- F. nucleatum infection mainly relies on antibiotics.
- antibiotics have the side effect of killing normal flora and therefore cannot be used for long periods of time.
- F.nucleatum as a commensal bacterium in humans, can easily return to a higher load in the human body, thereby increasing the risk of recurrence of acute and chronic infections and promoting the occurrence of various F.nucleatum-related diseases.
- the present invention provides a polypeptide for F. nucleatum, which can specifically kill F. nucleatum, has low antibacterial activity against other bacteria, and does not have the side effects of antibiotics killing normal flora. Therefore, the polypeptide can be used to limit the F. nucleatum load in the body for a long time, thereby achieving the treatment and prevention of various F. nucleatum-related diseases.
- FIG. 8 Electrospray mass spectrometry results of polypeptide P8 obtained in Example 1 of the present invention.
- FIG. 11 Electrospray mass spectrometry results of polypeptide P11 obtained in Example 1 of the present invention.
- FIG. 12 Electrospray mass spectrometry results of polypeptide P12 obtained in Example 1 of the present invention.
- Figure 13 is the chemical molecular formula structure of the antibacterial peptide P1 of the present invention.
- Figure 14 is the chemical molecular formula structure of the antibacterial peptide P2 of the present invention.
- Figure 15 is the chemical molecular formula structure of the antimicrobial peptide P3 of the present invention.
- Figure 16 is the chemical molecular formula structure of the antibacterial peptide P4 of the present invention.
- Figure 17 is the chemical molecular formula structure of the antibacterial peptide P5 of the present invention.
- Figure 18 is the chemical molecular formula structure of the antibacterial peptide P6 of the present invention.
- Figure 19 is the chemical molecular formula structure of the antibacterial peptide P7 of the present invention.
- Figure 20 is the chemical formula structure of the antibacterial peptide P8 of the present invention.
- Figure 21 is the chemical molecular formula structure of the antibacterial peptide P9 of the present invention.
- Figure 22 is the chemical molecular formula structure of the antibacterial peptide P10 of the present invention.
- Figure 23 is the chemical molecular formula structure of the antibacterial peptide P11 of the present invention.
- Figure 24 is the chemical molecular formula structure of the antibacterial peptide P12 of the present invention.
- Figure 25 Transmission electron microscope image results of F. nucleatum treated with polypeptide P7-P12 and the blank group (Mock) in Example 3 of the present invention
- Figure 26 shows the dynamic light scattering detection results of polypeptides P7-P12 in Example 4 of the present invention
- Figure 27 A schematic flowchart of the animal test procedure for treating F. nucleatum with polypeptides P8 and P11 in Example 5 of the present invention
- Figure 28 Statistical data results of tumor number (left) and tumor size (right) of mice in Example 5 of the present invention.
- the present invention improves antibacterial specificity by designing the amino acid distribution into a symmetrical structure.
- proline (P) and glycine (G) are used as the center to provide ⁇ -turns, so that the polypeptide obtains a ⁇ -sheet structure.
- the present invention uses hydrophobic amino acids to increase the self-assembly potential of the polypeptide; as a preferred option, tryptophan (W) is selected as the hydrophobic amino acid; as a preferred option, the proportion of hydrophobic amino acids is designed to be 40-44%.
- the present invention uses charged amino acids to adjust the total charge of the polypeptide to regulate the interaction between the polypeptide and the target microorganism; as a preferred solution, the total charge range of the polypeptide is designed to be from 0 to +8; as a preferred solution , the charged amino acids are designed to be arranged in intervals, and two adjacent charged amino acids with the same charge are arranged in an interval arrangement with one or more differently charged or uncharged amino acids. As a preferred solution, the total length of the polypeptide is designed to range from 10 to 20 amino acids. As a preferred solution, the amino acid sequences and various physical and chemical parameters of polypeptides P1-P12 are shown in Table 1.
- this application uses a solid-phase chemical synthesis method to sequentially synthesize polypeptides P1-P12.
- Polypeptide P1 is shown in SEQ ID NO.1
- polypeptide P2 is shown in SEQ ID NO.2
- polypeptide P3 is shown in SEQ ID NO.3.
- polypeptide P4 is shown in SEQ ID NO.4
- polypeptide P5 is shown in SEQ ID NO.5
- polypeptide P6 is shown in SEQ ID NO.6
- polypeptide P7 is shown in SEQ ID NO.7
- polypeptide P8 is shown in SEQ ID NO.8
- polypeptide P9 is shown as SEQ ID NO.9
- polypeptide P10 is shown as SEQ ID NO.10
- polypeptide P11 is shown as SEQ ID NO.11
- polypeptide P12 is shown as SEQ ID NO.12
- the solid-phase chemical synthesis method includes the following steps:
- Eluent A is 0.1% TFA/water solution
- eluent B is 0.1% TFA/acetonitrile solution
- the elution concentration is 25% B ⁇ 40%.
- B the elution time is 12min
- the flow rate is 1mL/min
- the main peak is collected as above and lyophilized;
- strains to be tested include Escherichia coli Nissile 1917, Vibrio cholerae H1, and Pseudomonas aeruginosa PAO1, Fusobacterium nucleatum 25586, Fusobacterium nucleatum 10953, Bifidobacterium uniformis 6597, Lactobacillus acidophilus 6075, Bifidobacterium longum 6194, Lactobacillus rhamnosus (Lactobacillus rhamnosus) 6141, Streptococcus agalactiae (Streptococcus agalactiae)
- polypeptides P6-P12 have antibacterial activity against F. nucleatum (the minimum inhibitory concentration is less than or equal to 64uM). Therefore, polypeptides P6-P12 can be called antibacterial peptides.
- polypeptides P8 and P11 have very strong antibacterial activity against F. nucleatum (the minimum inhibitory concentration is only 4 or 8 ⁇ M), but have weak antibacterial activity against other bacteria and have obvious bactericidal specificity. Therefore, polypeptides P8 and P11 can be called specific antimicrobial peptides against F. nucleatum.
- the self-assembly ability of P7-P12 was detected by dynamic light scattering: dissolve the peptide powder, dilute the peptide to be tested to 32 ⁇ M, sonicate for 15 minutes and put it into a sample bottle. After standing for 1 hour, insert the sample bottle into the sample bottle holder and wait for 10-15 minutes to make the temperature of the sample the same as that of the hot bath, and then perform the test, as shown in Figure 26.
- the results show that polypeptides P7-P12 can form self-assembled structures with linear dimensions of approximately 100-1000 nm. Among them, the linearity of polypeptides P8 and P11 exceeds 1000nm.
- this example uses a colorectal cancer animal model—C57BL APC min mice.
- the F.nucleatum-induced tumor model is shown in Figure 27: C57BL APC min mice were selected and F.nucleatum 25586 was gavaged into the mice three times a week as the F.nucleatum gavage group, and the control group was gavaged with an equal amount of PBS every week ( PBS gavage group), treated with 2.5% dextran sulfate sodium salt (DSS) for three consecutive days on the second day of gavage in the first week to increase F. nucleatum colonization;
- PBS gavage group PBS gavage group
- DSS dextran sulfate sodium salt
- mice were treated with antimicrobial peptide P8 or P11 by intragastric administration, and the control group was treated with pure water. Oral administration. Each mouse was intragastrically administered 20 mg/kg every day for 7 consecutive days, and then the mice were euthanized, and the number and size of tumors were recorded and counted. The results are shown in Figure 28.
- mice in the F.nucleatum gavage group (Fn+P8 and Fn+P11) treated with antimicrobial peptides P8 and P11 were smaller than those in the F.nucleatum gavage group treated with pure water.
- mice (Fn+H2O) the number of tumors was relatively small and the tumor diameter was small; and the number of tumors and tumor diameter bacteria were reduced to the level of the PBS gavage group without F. nucleatum.
- the experimental results show that treatment with antimicrobial peptides P8 and P11 has a preventive effect on colorectal cancer induced by F. nucleatum.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种多肽及其设计方法和在制备抑制具核梭杆菌(Fusobacterium nucleatum，简称F.nucleatum)产品或预防结直肠癌药物中的应用，涉及多肽领域。多肽包括有疏水基氨基酸和带电荷氨基酸，所述多肽的氨基酸序列分布为对称性结构。本申请获得的多肽以天然氨基酸残基为基本成分，具有固有的生物相容性和生物降解性，可以特异性杀灭F.nucleatum，而对其他细菌具有较低的抗菌活性，不具有抗生素杀灭正常菌群的副作用。因此，多肽可以用来长期限制体内F.nucleatum的载量，进而实现对多种F.nucleatum相关疾病的治疗和预防；同时具有杀菌速率快、无残留、无污染、分子组成高度灵活、免疫原性低等优点。
Description
本发明涉及多肽领域，尤其涉及一种多肽及其设计方法和在制备抑制具核梭杆菌(Fusobacterium nucleatum，简称F.nucleatum)产品或预防结直肠癌药物中的应用。
F.nucleatum主要存在于人类口腔中，是一种人类的有害共栖菌，直接参与急、慢性牙周炎、牙龈炎、根管感染等口腔疾病。F.nucleatum还被发现与一系列疾病相关，包括结直肠癌、炎症性肠病、阑尾炎等肠道疾病，以及呼吸道感染、不良妊娠后果、心血管疾病、脑动脉瘤、类风湿性关节炎，阿兹海默症等疾病。
虽然F.nucleatum可被广谱抗生素杀灭，急性F.nucleatum感染可被抗生素治愈，但是抗生素具有杀灭正常菌群的副作用，因此不能长期使用。一旦停用抗生素，F.nucleatum作为人类的共栖菌，极易在人类体内重新恢复到一个较高的载量，进而增加急、慢性感染复发的风险，以及促进上述F.nucleatum相关疾病的发生发展。
因此，急需对人体正常菌群无害、可以杀灭F.nucleatum的制剂，用以长期限制体内F.nucleatum的载量，进而实现对上述多种疾病的治疗和预防。
发明内容
为了解决上述技术问题，本发明针对F.nucleatum，提供了一种氨基酸序列呈对称性分布、且包含疏水性氨基酸和带电荷氨基酸的多肽。所述多肽中的一些版本对F.nucleatum具有抗菌活性，其中的一些版本更是具有针对F.
nucleatum的特异性杀菌作用。由于所述多肽针对F.nucleatum的特异性杀菌作用，且不会杀伤宿主正常菌群，所述多肽可被用于降低宿主体内的F.nucleatum载量，从而治疗或长期预防F.nucleatum相关疾病。
本发明目的之一：提供了一种多肽，所述多肽包括有疏水基氨基酸和带电荷氨基酸，所述多肽的氨基酸序列分布为对称性结构。
作为优选方案，所述多肽的氨基酸序列呈对称性分布在以脯氨酸和甘氨酸为中心的两侧，脯氨酸和甘氨酸提供β-转角，使多肽获得β-折叠结构。
作为优选方案，所述多肽的总电荷区间为0至+8。
作为优选方案，所述带电荷氨基酸包括带正电荷氨基酸和/或带负电荷氨基酸，所述带负电荷氨基酸为谷氨酸和/或天冬氨酸，所述带正电荷氨基酸为组氨酸、赖氨酸和精氨酸中的至少一种。
作为优选方案，相邻两个带同种电荷的带电荷氨基酸间隔排列设置有一个及以上带不同或不带电荷的氨基酸。
作为优选方案，所述疏水性氨基酸为色氨酸。
作为优选方案，所述疏水性氨基酸比例区间为40％-50％。
作为优选方案，所述多肽的总长度区间为10至20个氨基酸。
作为优选方案，所述多肽的氨基酸序列如SEQ ID NO.1、SEQ ID NO.2、SEQ ID NO.3、SEQ ID NO.4、SEQ ID NO.5、SEQ ID NO.6、SEQ ID NO.7、SEQ ID NO.8、SEQ ID NO.9、SEQ ID NO.10、SEQ ID NO.11或SEQ ID NO.12所示。
本发明目的之二：一种多肽的设计方法，包括以下步骤：
(1)固定疏水基氨基酸的种类和含量，设计氨基酸分布为对称性结构，挑选带电荷氨基酸的种类和含量；
(2)采用固相化学合成法通过多肽合成仪获得肽树脂，再经过TFA切割后，获得多肽。
本发明目的之三：一种多肽在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用。
作为优选方案，所述多肽包括氨基酸序列如SEQ ID NO.6、SEQ ID NO.7、SEQ ID NO.8、SEQ ID NO.9、SEQ ID NO.10、SEQ ID NO.11和SEQ ID NO.12所示中的一种或多种多肽，其对具核梭杆菌具有抑菌的作用，杀菌机制是通过破坏F.nucleatum的细胞壁实现的。
作为优选方案，所述多肽包括氨基酸序列如SEQ ID NO.8和/或SEQ ID NO.11所示的多肽，其具有针对F.nucleatum的特异性抗菌活性，即对除F.nucleatum之外的测试菌不具有或只具有较低的抗菌活性。
作为优选方案，当所述多肽的氨基酸序列如SEQ ID NO.8或SEQ ID NO.11所示时，所述多肽的用药剂量为20mg/kg，用药对象为小鼠。
相比于现有技术，本发明实施例具有如下有益效果：
目前在临床实践中，针对F.nucleatum感染的治疗主要依靠抗生素。然而，抗生素具有杀灭正常菌群的副作用，因此不能长期使用。一旦停用抗生素，F.nucleatum作为人类的共栖菌，极易在人类体内重新恢复到一个较高的载量，进而增加急、慢性感染复发的风险，以及促进各种F.nucleatum相关疾病的发生发展。本发明针对F.nucleatum，提供了一种多肽，可以特异性杀灭F.nucleatum，而对其他细菌具有较低的抗菌活性，不具有抗生素杀灭正常菌群的副作用。因此，所述多肽可以用来长期限制体内F.nucleatum的载量，进而实现对多种F.nucleatum相关疾病的治疗和预防。
图1：为本发明实施例一中获得多肽P1的电喷雾质谱结果；
图2：为本发明实施例一中获得多肽P2的电喷雾质谱结果；
图3：为本发明实施例一中获得多肽P3的电喷雾质谱结果；
图4：为本发明实施例一中获得多肽P4的电喷雾质谱结果；
图5：为本发明实施例一中获得多肽P5的电喷雾质谱结果；
图6：为本发明实施例一中获得多肽P6的电喷雾质谱结果；
图7：为本发明实施例一中获得多肽P7的电喷雾质谱结果；
图8：为本发明实施例一中获得多肽P8的电喷雾质谱结果；
图9：为本发明实施例一中获得多肽P9的电喷雾质谱结果；
图10：为本发明实施例一中获得多肽P10的电喷雾质谱结果；
图11：为本发明实施例一中获得多肽P11的电喷雾质谱结果；
图12：为本发明实施例一中获得多肽P12的电喷雾质谱结果；
图13：为本发明抗菌肽P1的化学分子式结构；
图14：为本发明抗菌肽P2的化学分子式结构；
图15：为本发明抗菌肽P3的化学分子式结构；
图16：为本发明抗菌肽P4的化学分子式结构；
图17：为本发明抗菌肽P5的化学分子式结构；
图18：为本发明抗菌肽P6的化学分子式结构；
图19：为本发明抗菌肽P7的化学分子式结构；
图20：为本发明抗菌肽P8的化学分子式结构；
图21：为本发明抗菌肽P9的化学分子式结构；
图22：为本发明抗菌肽P10的化学分子式结构；
图23：为本发明抗菌肽P11的化学分子式结构；
图24：为本发明抗菌肽P12的化学分子式结构；
图25：为本发明实施例三中经多肽P7-P12处理及空白组(Mock)的F.nucleatum的透视电子显微镜图像结果；
图26：为本发明实施例四中多肽P7-P12的动态光散射检测结果；
图27：为本发明实施例五中多肽P8和P11处理F.nucleatum动物试验流程示意图；
图28：为本发明实施例五中小鼠的肿瘤数(左)及肿瘤大小(右)统计数据结果。
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例一
多肽P1-P12的设计与制备：
设计方面，本发明通过设计氨基酸分布为对称性结构以提高抗菌特异性，作为优选方案，以脯氨酸(P)及甘氨酸(G)作为中心，提供β-转角，使多肽获得β-折叠结构。另外，本发明采用了疏水氨基酸，以增加该多肽的自组装潜力；作为优选方案，疏水氨基酸选用色氨酸(W)；作为优选方案，疏水氨基酸比例设计为40-44％。同时，本发明采用了带电荷氨基酸，对多肽的总电荷进行调节，以调控多肽与目标微生物之间的相互作用力；作为优选方案，多肽的总电荷区间设计为0至+8；作为优选方案，带电荷氨基酸设计为间隔排列，相邻两个带同种电荷的带电荷氨基酸间隔排列设置有一个及以上带不同或不带电荷的氨基酸。作为优选方案，多肽总长度区间设计为10至20个氨基酸。作为优选方案，多肽P1-P12的氨基酸序列与各项理化参数如表1所示。
表1-多肽P1-P12的序列及各项理化参数
制备方面，本申请采用固相化学合成法依次合成多肽P1-P12，多肽P1如SEQ ID NO.1所示，多肽P2如SEQ ID NO.2所示，多肽P3如SEQ ID NO.3所示，多肽P4如SEQ ID NO.4所示，多肽P5如SEQ ID NO.5所示，多肽P6如SEQ ID NO.6所示，多肽P7如SEQ ID NO.7所示，多肽P8如SEQ ID NO.8所示，多肽P9如SEQ ID NO.9所示，多肽P10如SEQ ID NO.10所示，多肽P11如SEQ ID NO.11所示，多肽P12如SEQ ID NO.12所示，固相化学合成法包括以下步骤：
1、按照多肽的氨基酸序列从C端到N端逐一进行，通过多肽合成仪来完成，首先将Fmoc-X(X是每个多肽的C端第一个氨基酸)接入到Wang树脂，然后脱去Fmoc基团后得到X-Wang树脂；再将Fmoc-Y-Trt-OH(9-芴甲氧羧基-三甲基-Y，Y为每个抗菌肽C端第二个氨基酸)；按照这个程序依次从C端合成到N端，直至合成完毕，得到脱去Fmoc基团的侧链保护的肽树脂；
2、在上述得到的肽树脂中，加入切割试剂，20℃避光下反应2h，过滤；沉淀TFA(三氟乙酸)洗涤，将洗液与上述滤液混合，旋转蒸发仪浓缩，再加入10倍左右体积的预冷无水乙醚，-20℃沉淀3h，析出白色粉末物，以2500g离心10min，收集沉淀，再用无水乙醚洗涤沉淀，真空干燥，得到多肽，其中切割试剂由TFA、水和TIS(三异丙基氯硅烷)按照质量比95:2.5:2.5混合而成；
3、使用0.2mol/L硫酸钠(磷酸调节至pH7.5)进行柱平衡30min，用90％乙腈水溶液溶解多肽，过滤，C18反相常压柱，采用梯度洗脱(洗脱剂为甲醇和硫酸钠水溶液按照体积比为30:70～70:30混合)，流速为1mL/min，检测波为
220nm，收集主峰，冻干；再利用反相C18柱进一步纯化，洗脱液A为0.1％TFA/水溶液；洗脱液B为0.1％TFA/乙腈溶液，洗脱浓度为25％B～40％B，洗脱时间为12min，流速为1mL/min，再同上收集主峰，冻干；
4、多肽的鉴定：将上述得到的多肽经过电喷雾质谱法分析，结果如图1-12所示，多肽P1-P12的纯度均大于95％，多肽P1-P12的化学结构式如图13-24所示。
实施例二
多肽P1-P12体外抗菌活性的测定：
1、抗菌活性的测定：
A、将多肽配置成为一定储存液以备使用，利用微量肉汤稀释法测定抗多肽P1-P12的最小抑菌浓度，以0.01％乙酸(含0.2％BSA)作为稀释液，使用二倍稀释法依次配置系列梯度的抗菌肽溶液；
B、取上述储备多肽溶液100μL置于96孔细胞培养板中，然后分别添加等体积的待测菌液(约105个/mL)于各孔中，分别设置阳性对照(含有菌液而不含有多肽)和阴性对照(既不含菌液也不含多肽)，待测菌种包括大肠杆菌(Escherichia coli)Nissile 1917、霍乱弧菌(Vibrio cholerae)H1、铜绿假单胞菌(Pseudomonas aeruginosa)PAO1、具核梭杆菌(Fusobacterium nucleatum)25586、具核梭杆菌(Fusobacterium nucleatum)10953、单形拟杆菌(Bifidobacterium uniformis)6597、嗜酸乳杆菌(Lactobacillus acidophilus)6075、长双歧杆菌(Bifidobacterium longum)6194、鼠李糖乳杆菌(Lactobacillus rhamnosus)6141、无乳链球菌(Streptococcus agalactiae)H94；
C、将培养板置于37℃恒温培养20h，以肉眼未见孔底部有混浊现象的即为最小抑菌浓度，结果如表2所示。
表2-多肽P1-P12的最小抑菌浓度
通过表2可以看出，多肽P6-P12对F.nucleatum具有抗菌活性(最小抑菌浓度小于或等于64uM)，因此，多肽P6-P12可被称为抗菌肽。值得制出的是，多肽P8和P11，对F.nucleatum具有非常强的抗菌活性(最小抑菌浓度只需4或8μM)，而对其它菌的抗菌活性较弱，具有明显的杀菌特异性。因此，多肽P8和P11可被称为针对F.nucleatum的特异性抗菌肽。
实施例三
多肽P7-P12抗菌机制的测定：
A、将处于对数生长期的F.nucleatum 25586菌体在1000g条件下离心5min，并用无菌PBS反复冲洗3遍，重悬至OD600＝0.2；
B、将多肽样品加入40ml以上准备的菌液中，且保证其终浓度达到1×MIC(最低抑菌浓度)，37℃条件下置于摇床孵育1h；
C、将孵育后的菌液5000g条件下离心5min收集菌体细胞，PBS冲洗三遍后，吸干缓冲液并立刻向菌体沉淀中加入500μL 2.5％戊二醛将菌体重悬，4℃避光过夜；
D、将经过前固定过夜的样品离心收集沉淀，随后用无菌PBS冲洗3遍以出去残余前固定液，加入锇酸进行后固定，60-120min后再将样品离心收集沉淀(因锇酸为生物安全限制试剂，去除的锇酸固定液要小心回收处理)，并用无菌
PBS冲洗3遍以除去残余后固定液，继续用梯度乙醇溶液依次处理8-10分钟梯度脱水，随后用100％乙醇、乙醇和丙酮(1:1)混合溶液、100％叔丁醇依次分别置换10min，置换后加入丙酮和树脂(1：1)混合液处理30min，然后再用纯树脂包埋，过夜；
E、用醋酸铀和柠檬酸铅对样品染色后，制作超薄切片，最后用透射电子显微镜观察菌体膜及内部结构变化，结果如图13所示。
如图25中结果显示，经多肽P7-P12处理后的F.nucleatum细胞出现明显空洞，质壁分离，细胞膜破裂；而未经处理的细胞饱满，细胞壁结构完整。该结果表示，多肽P7-P12作用于F.nucleatum细胞壁，可使细胞膜破裂从而实现杀菌。
实施例四
多肽P7-P12自组装性的测定：
P7-P12的自组装能力用动态光散射检测：溶解多肽粉末，并将待测多肽稀释至32μM，超声15分钟后放入样品瓶。静置1小时后，将样品瓶插入样品瓶支架后，需等待10-15分钟，使样品的温度和热浴相同，随后进行检测，如图26。结果显示，多肽P7-P12可以形成自组装结构，线度约为100-1000nm这两个数量级。其中多肽P8与P11的线度超过1000nm。
实施例五
多肽P8与P11体内活性的测定：
A、为验证F.nucleatum特异性抗菌肽在体内对F.nucleatum的抗菌作用，尤其是对F.nucleatum所致疾病的预防作用，本实施例使用了结直肠癌动物模型——C57BL APCmin小鼠F.nucleatum诱导成瘤模型，如图27所示：选取C57BL APCmin小鼠，每周灌胃小鼠F.nucleatum 25586三次作为F.nucleatum灌胃组，对照组每周灌胃等量PBS(PBS灌胃组)，第一周开始灌胃的第二天用2.5％硫酸葡聚糖钠盐(Dextran sulfate，DSS)连续处理三天，以提高F.nucleatum定植；
B、在第6周开始对小鼠进行抗菌肽P8或P11灌胃治疗，对照组进行纯水
灌胃。每天每只灌胃20mg/kg，连续灌胃7天，随后安乐死小鼠，记录统计肿瘤数及其大小，结果如图28所示。
如图28所示，经抗菌肽P8和P11灌胃治疗后的F.nucleatum灌胃组小鼠(Fn+P8和Fn+P11),相对于纯水灌胃后的F.nucleatum灌胃组小鼠(Fn+H2O)，其肿瘤数相对较少，肿瘤直径较小；且肿瘤数量、肿瘤直径菌减少到了未经F.nucleatum灌胃的PBS灌胃组的程度。该实验结果表明，抗菌肽P8和P11的治疗对F.nucleatum诱导的结直肠癌具有预防作用。
以上所述的具体实施例，对本发明的目的、技术方案和有益效果进行了进一步的详细说明，应当理解，以上所述仅为本发明的具体实施例而已，并不用于限定本发明的保护范围。特别指出，对于本领域技术人员来说，凡在本发明的精神和原则之内，所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (10)
- 一种多肽，其特征在于，所述多肽包括有疏水基氨基酸和带电荷氨基酸，所述多肽的氨基酸序列分布为对称性结构。
- 如权利要求1所述的一种多肽，其特征在于，所述多肽的氨基酸序列呈对称性分布在以脯氨酸和甘氨酸为中心的两侧，所述脯氨酸和甘氨酸提供β-转角，使多肽获得β-折叠结构。
- 如权利要求1所述的一种多肽，其特征在于，所述多肽的总电荷区间为0至+8。
- 如权利要求3所述的一种多肽，其特征在于，所述带电荷氨基酸包括带正电荷氨基酸和/或带负电荷氨基酸，所述带负电荷氨基酸为谷氨酸和/或天冬氨酸，所述带正电荷氨基酸为组氨酸、赖氨酸和精氨酸中的至少一种，相邻两个带同种电荷的带电荷氨基酸间隔排列设置有一个及以上带不同或不带电荷的氨基酸。
- 如权利要求1所述的一种多肽，其特征在于，所述疏水基氨基酸比例区间为40％-50％，所述疏水基氨基酸为色氨酸。
- 如权利要求1所述的一种多肽，其特征在于，所述多肽的总长度区间为10-20个氨基酸。
- 如权利要求1-6任一所述的一种多肽，其特征在于，所述多肽的氨基酸序列如SEQ ID NO.1、SEQ ID NO.2、SEQ ID NO.3、SEQ ID NO.4、SEQ ID NO.5、SEQ ID NO.6、SEQ ID NO.7、SEQ ID NO.8、SEQ ID NO.9、SEQ ID NO.10、SEQ ID NO.11或SEQ ID NO.12所示。
- 一种如权利要求1-7任一所述的多肽的设计方法，其特征在于，包括以下步骤：(1)固定疏水基氨基酸的种类和含量，设计氨基酸分布为对称性结构，挑选带电荷氨基酸的种类和含量；(2)采用固相化学合成法通过多肽合成仪获得肽树脂，再经过TFA切割后，获得多肽。
- 一种如权利要求1-7任一所述的多肽在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用。
- 如权利要求9所述的一种多肽在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用，其特征在于，所述多肽包括氨基酸序列如SEQ ID NO.6、SEQ ID NO.7、SEQ ID NO.8、SEQ ID NO.9、SEQ ID NO.10、SEQ ID NO.11和SEQ ID NO.12所示的一种或多种多肽。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210684148.6A CN114989254B (zh) | 2022-06-17 | 2022-06-17 | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 |
| CN202210684148.6 | 2022-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023241675A1 true WO2023241675A1 (zh) | 2023-12-21 |
Family
ID=83035198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/100589 WO2023241675A1 (zh) | 2022-06-17 | 2023-06-16 | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114989254B (zh) |
| WO (1) | WO2023241675A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114989254B (zh) * | 2022-06-17 | 2023-11-03 | 中山大学 | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923189A (zh) * | 2014-04-11 | 2014-07-16 | 东北农业大学 | 一种猪源抗菌肽的衍生肽ir2及其制备方法和应用 |
| CN107746429A (zh) * | 2017-11-09 | 2018-03-02 | 东北农业大学 | 一种末端对称抗菌肽pp及其制备方法和应用 |
| CN108276485A (zh) * | 2018-03-22 | 2018-07-13 | 东北农业大学 | 能抑制和杀灭革兰氏阴性菌的抗菌肽hv2及制备方法 |
| CN111423492A (zh) * | 2020-03-30 | 2020-07-17 | 东北农业大学 | 含D型脯氨酸和甘氨酸转角的β发卡抗菌肽及制备方法 |
| WO2021220011A1 (en) * | 2020-05-01 | 2021-11-04 | Bicycletx Limited | Anti-infective bicyclic peptide conjugates |
| CN114989254A (zh) * | 2022-06-17 | 2022-09-02 | 中山大学 | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003250578A (ja) * | 2001-12-26 | 2003-09-09 | Toyota Central Res & Dev Lab Inc | 抗菌性ポリペプチドおよびこのポリペプチドを含有する抗菌剤 |
| KR100863090B1 (ko) * | 2002-01-17 | 2008-10-13 | 다케다 파머수티컬 컴패니 리미티드 | 항증식 활성을 지니고／지니거나 핵산 손상제 또는 처리제를 증강시키는 펩티드 및 펩티드모방체 |
| ITMI20122263A1 (it) * | 2012-12-28 | 2014-06-29 | Azienda Ospedaliero Universitaria Di Parma | Nuovi peptidi cationici ciclici ad attività antimicrobica |
| WO2015161820A1 (zh) * | 2014-04-24 | 2015-10-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 两亲性合成抗菌肽、其药物组合物及其用途 |
| US10017542B2 (en) * | 2015-03-23 | 2018-07-10 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of use thereof |
| CN105779471A (zh) * | 2015-11-12 | 2016-07-20 | 中山大学 | 具核梭杆菌AhpC蛋白的克隆表达及其应用 |
| CN106749532A (zh) * | 2016-11-25 | 2017-05-31 | 东北农业大学 | 具有耐受蛋白酶的多股β‑发卡短肽及制备方法和应用 |
| CN106749531A (zh) * | 2016-11-25 | 2017-05-31 | 东北农业大学 | 色氨酸拉链β‑发卡抗菌肽及其制备方法和与应用 |
| CN108690864A (zh) * | 2017-10-31 | 2018-10-23 | 中山大学 | 一种粪便样本中菌群稳态评价方法及在结直肠癌筛查中的应用 |
| CN109232717B (zh) * | 2018-08-31 | 2021-08-20 | 东北农业大学 | 一种针对革兰氏阴性菌靶向抗菌肽及制作方法与应用 |
| CN111363010B (zh) * | 2020-03-30 | 2023-10-13 | 倪京满 | 一类对称短序列抗菌肽类似物及其应用 |
| WO2021234471A1 (en) * | 2020-05-17 | 2021-11-25 | Abgenics Lifesciences Private Limited | An antibody fragment based antimicrobial conjugate selectively targeting pseudomonas |
-
2022
- 2022-06-17 CN CN202210684148.6A patent/CN114989254B/zh active Active
-
2023
- 2023-06-16 WO PCT/CN2023/100589 patent/WO2023241675A1/zh unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923189A (zh) * | 2014-04-11 | 2014-07-16 | 东北农业大学 | 一种猪源抗菌肽的衍生肽ir2及其制备方法和应用 |
| CN107746429A (zh) * | 2017-11-09 | 2018-03-02 | 东北农业大学 | 一种末端对称抗菌肽pp及其制备方法和应用 |
| CN108276485A (zh) * | 2018-03-22 | 2018-07-13 | 东北农业大学 | 能抑制和杀灭革兰氏阴性菌的抗菌肽hv2及制备方法 |
| CN111423492A (zh) * | 2020-03-30 | 2020-07-17 | 东北农业大学 | 含D型脯氨酸和甘氨酸转角的β发卡抗菌肽及制备方法 |
| WO2021220011A1 (en) * | 2020-05-01 | 2021-11-04 | Bicycletx Limited | Anti-infective bicyclic peptide conjugates |
| CN114989254A (zh) * | 2022-06-17 | 2022-09-02 | 中山大学 | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114989254B (zh) | 2023-11-03 |
| CN114989254A (zh) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9872885B2 (en) | Antimicrobial and anti-inflammatory peptides | |
| US6465429B1 (en) | Antimicrobial cationic peptides | |
| AU2002324752B2 (en) | Antimicrobial cationic peptides and formulations thereof | |
| JP5270150B2 (ja) | 細菌感染の治療 | |
| ES2952858T3 (es) | Nuevos polipéptidos y uso médico de los mismos | |
| US20230107222A1 (en) | Engineered antimicrobial amphiphilic peptides and methods of use | |
| WO2023241675A1 (zh) | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 | |
| JP2002524393A (ja) | ゾヌリンのペプチドアンタゴニストおよびその使用方法 | |
| AU759026B2 (en) | Antimicrobial peptides | |
| AU2002328203A1 (en) | Antimicrobial and anti-inflammatory peptides | |
| US20220249599A1 (en) | Treatment of implants with engineered antimicrobial amphiphilic peptides | |
| ES2256070T3 (es) | Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana. | |
| JP5384948B2 (ja) | 新規ポリペプチド及びそれを有効成分として含有する抗菌剤 | |
| TWI593704B (zh) | 具有抗病原菌功效的抗菌胜肽及其製藥用途 | |
| Scavello et al. | The antimicrobial peptides secreted by the chromaffin cells of the adrenal medulla link the neuroendocrine and immune systems: From basic to clinical studies | |
| CN109535227B (zh) | 抗菌肽、抗菌肽制备方法、抗菌组合物、抗菌方法和应用 | |
| JP2020528426A (ja) | 感染症治療用ラクトフェリシン及びラクトフェランピン | |
| CN107827957B (zh) | 抗临床多重耐药菌小肽 | |
| US10100086B2 (en) | Peptide and uses thereof | |
| CN113198004B (zh) | 一种修复肠粘膜的凝结芽孢杆菌制剂 | |
| CN109627312B (zh) | 一种新型抗菌肽及其应用 | |
| CN117024607A (zh) | 一种用于抗菌的多肽药物及其应用 | |
| JPH07309771A (ja) | 非経口用抗腫瘍剤 | |
| CN115746097A (zh) | 抗菌肽as-12w及其制备方法和用途 | |
| CN116789754A (zh) | 一种基于细菌感染的多肽铜抗菌材料的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23823241 Country of ref document: EP Kind code of ref document: A1 |